Patient Experience Data (PED) in 2019-2023 US FDA NME Drug Approvals: Analysis and Recommendations.
Saved in:
| Title: | Patient Experience Data (PED) in 2019-2023 US FDA NME Drug Approvals: Analysis and Recommendations. |
|---|---|
| Authors: | Martin JD; BioMarin (United States), San Rafael, CA, USA. jewell.martin@bmrn.com., Frear D; BridgeBio (United States), Palo Alto, USA., Roberts SA; AstraZeneca (United States), Gaithersburg, MD, USA.; Genentech, Washington, DC, USA., Dohnal VA; Johnson & Johnson (United States), New Brunswick, USA., Kieffer C; Takeda (United States), Cambridge, MA, USA., Morin SL; Merck & Co., Inc., Rahway, NJ, USA., Lock I; Genentech, Washington, DC, USA., Balogun A; Johnson & Johnson (United States), New Brunswick, USA., Chhina N; BioMarin (United States), San Rafael, CA, USA.; Teva Pharmaceuticals (United States), Parsippany, NJ, USA. |
| Source: | Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2025 Jul; Vol. 59 (4), pp. 859-870. Date of Electronic Publication: 2025 May 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101597411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2168-4804 (Electronic) Linking ISSN: 21684790 NLM ISO Abbreviation: Ther Innov Regul Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2168-4804 |
|---|---|
| DOI: | 10.1007/s43441-025-00788-w |
